Modeling restoration of gefitinib efficacy by co‐administration of MET inhibitors in an EGFR inhibitor‐resistant NSCLC xenograft model: A tumor‐in‐host DEB‐based approach

• Main Authors: Elena M. Tosca (Author), Glenn Gauderat (Author), Sylvain Fouliard (Author), Mike Burbridge (Author), Marylore Chenel (Author), Paolo Magni (Author)
• Format: Book
• Published: Wiley, 2021-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract MET receptor tyrosine kinase inhibitors (TKIs) can restore sensitivity to gefitinib, a TKI targeting epidermal growth factor receptor (EGFR), and promote apoptosis in non‐small cell lung cancer (NSCLC) models resistant to gefitinib treatment in vitro and in vivo. Several novel MET inhibitor...